Myeloma Mentors: Charting New Paths in Relapsed/Refractory Multiple Myeloma Care

Earn up to 0.75 AMA PRA Credit
About the Program
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions

Program Overview

Advances in bispecific antibodies (BsAbs) and CAR T-cell therapy continue to reshape the management of relapsed/refractory multiple myeloma (RRMM). As these options expand, clinicians face practical challenges—integrating novel agents into individualized care plans, sequencing therapies effectively, and managing toxicities such as CRS and ICANS. Differences in protocols and transitions between academic and community settings can further complicate continuity of care.

This 47-minute webcast features expert perspectives from the University of Colorado Hematology Division and offers clear, evidence-informed guidance on the real-world use of BsAbs in RRMM. Through focused discussions, viewers will gain actionable insights on therapy selection, sequencing considerations, toxicity monitoring, and coordination across care environments.

Designed to support clinicians practicing in diverse settings, this program aims to strengthen decision-making, enhance collaboration, and improve the delivery of consistent, high-quality care for patients with RRMM.

Target Audience

This educational program is directed at hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM. 

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Johnson and Johnson.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.
  • Construct patient-specific treatment sequences incorporating BsAbs into existing treatment plans based on prior treatments, disease characteristics, and comorbidities.
  • Implement evidence-based strategies for mitigating and managing CRS and neurological toxicities associated with BsAbs in both inpatient and outpatient settings, including step-up dosing protocols, specific monitoring parameters, and thresholds for intervention.
  • Formulate a structured communication plan between academic and community practitioners to ensure safe transitions of care for patients receiving BsAbs.

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Joseph Mikhael, MD, Med, FRCPC,
FACP, FASCO
Professor, Translational Genomics Research Institute 
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona
Consulting Fee (e.g, Advisory Board):
BMS, Janssen, Menarini, Sanofi

Instructions to Receive Credit

In order to receive credit for this activity, the participant must: 

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Participate by completing the webcast
  • Complete the posttest with a score of 70% or higher
  • Complete the evaluation

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
Stay current with the evolving treatment landscape of relapsed/refractory multiple myeloma (RRMM) in this 47-minute expert-led webcast. Dr. Joseph Mikhael reviews the advancing role of bispecific antibodies, key considerations for sequencing therapies, and practical approaches to coordinating care across academic and community settings. Designed for busy clinicians, this session offers clear, evidence-informed insights to support real-world decision-making and improve continuity of care.

Target Audience

This educational program is directed at hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM. 
This educational activity is supported by an educational grant from
Johnson & Johnson.

Maximum Credit Amount: 0.75

Credit Type: ACCME, ANCC
Release: 12/1/2025
Expiration: 12/1/2026